礼来公布头对头研究详细结果：替尔泊肽减重和降低腰围均优于司美格鲁肽

Core Viewpoint - Eli Lilly announced detailed results from the SURMOUNT-5 study, demonstrating the efficacy and safety of tirzepatide compared to semaglutide in overweight adults with obesity and at least one comorbidity [1] Group 1: Study Overview - The SURMOUNT-5 study is an open-label Phase 3b clinical trial [1] - The trial aimed to evaluate the effectiveness of the GLP/GLP-1 dual receptor agonist tirzepatide against the GLP-1 single receptor agonist semaglutide [1] - Participants included overweight adults with obesity and at least one comorbidity, excluding those with diabetes [1] Group 2: Results - At week 72, tirzepatide achieved the primary endpoint and all five key secondary endpoints [1] - Throughout the trial, tirzepatide demonstrated superiority over semaglutide [1]